Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.

J Rosenstock, V Fonseca, J B McGill, M Riddle, J P Hallé, I Hramiak, P Johnston, M Davis

Journal: Diabetologia 2010;52(9):1971-3

PMID: 19609501

Free Full Text on PubMed Central View on PubMed

Abstract

DOI: 10.1007/s00125-009-1452-2

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/diabetestype2.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Diabetes Mellitus, Type 2, Diabetic Retinopathy, Humans, Hypoglycemic Agents, Insulin, Insulin Glargine, Insulin, Isophane, Insulin, Long-Acting, Neoplasms, Risk Factors

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

Sponsor

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.